Clinical Scorecard: Evaluation of Computationally Identified Small Molecules Targeting the YAP–TEAD Interaction in Mesothelioma Cell Models with Altered Hippo Pathway Activity

At a Glance

Key Highlights

• TEAD inhibitors like K-975 showed dose-dependent antiproliferative effects in certain mesothelioma cell lines.
• Computationally nominated compounds did not demonstrate measurable antiproliferative activity.
• The study highlights the disparity between computational predictions and actual cellular activity.
• Negative validation findings are infrequently reported in drug discovery.
• YAP/TAZ signaling contributes to therapeutic resistance in various cancers.

Guideline-Based Recommendations

Diagnosis

• Assess Hippo pathway alterations in mesothelioma for targeted therapy considerations.

Management

• Consider TEAD inhibitors for patients with Hippo pathway alterations.

Monitoring & Follow-up

• Monitor cell viability and proliferation in response to TEAD inhibitors.

Risks

• Potential for publication bias in reporting negative validation findings.

Patient & Prescribing Data

Patients with malignant pleural mesothelioma exhibiting Hippo pathway dysregulation.

K-975 and cisplatin are validated treatments, while computationally nominated compounds showed no activity.

Clinical Best Practices

• Utilize both positive and negative findings to inform drug discovery efforts.
• Incorporate structure-guided virtual screening in the identification of drug candidates.

Related Resources & Content

• Study on Hippo Pathway and TEAD Inhibition